NLRP3 and COVID-19: With COVID-19 patients known to manifest neurological symptoms and NLRP3 known to be implicated in neurological diseases like Alzheimer’s (Heneka et al. 2013)—blocking IL-1 can conceivably be more efficacious than IL-6 in managing COVID-19.